People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

47.81USD
10 Jul 2014
Price Change (% chg)

$-0.90 (-1.85%)
Prev Close
$48.71
Open
$47.74
Day's High
$48.69
Day's Low
$47.74
Volume
519,521
Avg. Vol
893,480
52-wk High
$54.25
52-wk Low
$28.86

Search Stocks

Summary

Name Age Since Current Position

Richard Pops

52 2011 Chairman of the Board, Chief Executive Officer

Shane Cooke

51 2011 President

James Frates

46 2011 Chief Financial Officer, Senior Vice President

Gordon Pugh

55 2011 Chief Operating Officer, Senior Vice President, Chief Risk Officer

Kathryn Biberstein

54 2011 Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

Rebecca Peterson

38 Senior Vice President

James Botkin

64 2011 Senior Vice President - Operations

Elliot Ehrich

54 2011 Senior Vice President - Research and Development, Chief Medical Officer

Michael Landine

59 2011 Senior Vice President - Corporate Development

Srdjan Stankovic

56 2013 Senior Vice President - Clinical Development

Mark Stejbach

50 2012 Senior Vice President, Chief Commercial Officer

Peter Norman

2013 Vice President - Government Affairs and Policy

Paul Mitchell

60 2012 Lead Independent Director

Nancy Wysenski

56 2013 Director

David Anstice

65 2011 Independent Director

Floyd Bloom

76 2011 Independent Director

Robert Breyer

69 2011 Independent Director

Wendy Dixon

58 2011 Independent Director

Geraldine Henwood

59 2011 Independent Director

Biographies

Name Description

Richard Pops

Mr. Richard F. Pops is Chairman of the Board, Chief Executive Officer of Alkermes Plc. Until September 16, 2011, Mr. Pops was Chief Executive Officer, President and Chairman of the Board of Alkermes. Mr. Pops served as Chief Executive Officer of Alkermes from February 1991 to April 2007 and as Chief Executive Officer and President since September 2009. He was a director of Alkermes from February 1991 to September 2011 and was Chairman of the Board of Alkermes since April 2007. Mr. Pops serves on the board of directors of Neurocrine Biosciences, Inc., a publicly traded biopharmaceutical company, Acceleron Pharma, Inc. and Epizyme Inc., both of which are privately held biotechnology companies, Biotechnology Industry Organization, and PhRMA. He has previously served on the board of directors of two other publicly traded biopharmaceutical companies, Sirtris Pharmaceuticals from 2004 to 2008, and CombinatoRx, Incorporated from 2001 to 2009. Mr. Pops served on the board of directors of Reliant Pharmaceuticals, a privately held pharmaceutical company purchased by GlaxoSmithKline in 2007, and on the advisory board of Polaris Venture Partners. He is a member of the Harvard Medical School Board of Fellows.

Shane Cooke

Mr. Shane Cooke is President of Alkermes Plc. He is employed by Alkermes Pharma Ireland Limited, an Irish subsidiary of the company. From May 2005 to September 16, 2011, Mr. Cooke served as a Director of Elan. From May 2007 to September 16, 2011, Mr. Cooke was Executive Vice President of Elan and Head of EDT and had been Chief Financial Officer of Elan from July 2001, when he joined Elan, until May 2011. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that held a number of senior positions in finance in the banking and aviation industries. He is a chartered accountant.

James Frates

Mr. James M. Frates is Chief Financial Officer, Senior Vice President of Alkermes Plc. Until September 16, 2011, Mr. Frates was Senior Vice President, Chief Financial Officer and Treasurer of Alkermes. From June 1998 to May 2007, Mr. Frates served as Vice President, Chief Financial Officer and Treasurer of Alkermes. From June 1996 to June 1998, he was employed at Robertson, Stephens & Company, most recently as a Vice President in Investment Banking. Prior to that time he was employed at Morgan Stanley & Co. Mr. Frates served on the Board of Directors of GPC Biotech AG, a biotechnology company, from June 2004 to 2009, and was a national director of the Association of Bioscience Financial Officers from 2004 to 2009. Mr. Frates is a Trustee of St. Paul's School.

Gordon Pugh

Mr. Gordon G. Pugh is Chief Operating Officer, Senior Vice President, Chief Risk Officer of Alkermes Plc. Until September 16, 2011, Mr. Pugh served as Senior Vice President, Chief Operating Officer and Chief Risk Officer of Alkermes. In that role, he was responsible for the operations departments of Alkermes. Additionally, he oversaw site management in Waltham, Massachusetts, and Wilmington, Ohio. Prior to assuming the Senior Vice President and Chief Operating Officer positions in May 2007 and the Chief Risk Officer position in July 2010, Mr. Pugh served as Vice President of Operations at Alkermes. Mr. Pugh has over 30 years of operations and manufacturing experience. For the eight-year period prior to joining Alkermes, Mr. Pugh worked at Lonza Biologics, Inc., a publicly traded life sciences company, as the Vice President of manufacturing operations in the United States and Europe. Mr. Pugh has served on the board of directors of KC Bio LLC, a privately held company, since 2000.

Kathryn Biberstein

Ms. Kathryn L. Biberstein is Senior Vice President, Chief Compliance Officer, General Counsel, Secretary of Alkermes PLC. Until September 16, 2011, she was Senior Vice President, Government Relations and Public Policy, General Counsel and Secretary and Chief Compliance Officer of Alkermes. From March 2003 to May 2007, Ms. Biberstein served as Vice President and General Counsel of Alkermes. She was Of Counsel at Crowell & Moring LLC from February 2002 to February 2003 and performed legal consulting services for various clients from March 2000 to February 2002. She was employed by Serono S.A., a biotechnology company, as General Counsel from 1993 to March 2000, where she was a member of the Executive Committee.

Rebecca Peterson

Ms. Rebecca J. Peterson is Senior Vice President - Corporate Communications of Alkermes plc. She worked at Millennium Pharmaceuticals from 1997 to 2000 and was Manager of Corporate Communications at Millennium Pharmaceuticals from October 1999 to October 2000. Ms. Peterson worked in the public affairs office at Brigham and Women's Hospital in 1997. She has been a Communications Committee Member for BIO since 2002 and a member of National Investor Relations Institute since 1998.

James Botkin

Mr. James L. Botkin is Senior Vice President - Operations of Alkermes Plc. He is employed by Alkermes Gainesville LLC. Until September 16, 2011, Mr. Botkin was Senior Vice President, Head of Operations of EDT, having been appointed in June 2007. He was formerly Vice President and General Manager of Elan's operations in Gainesville, Georgia from October 2001 to June 2007, President of Sharp Corporation, a private pharmaceutical packaging company, from January 1996 to June 2001, as well as Vice President, United States Production Operations of Sandoz Pharmaceutical Corporation from January 1993 to December 1995. Mr. Botkin has 40 years of experience in pharmaceutical industry operations. Mr. Botkin is a former Director of FirsTier Bank, Lincoln General Hospital and the Healthcare Compliance Packaging Council.

Elliot Ehrich

Dr. Elliot W. Ehrich is Senior Vice President - Research and Development, Chief Medical Officer of Alkermes Plc. Until September 16, 2011, Dr. Ehrich served Senior Vice President of Research and Development and Chief Medical Officer at Alkermes. From May 2007 to September 2011, Dr. Ehrich also led the Research and Development, Clinical Sciences and Drug Safety functions at Alkermes. Prior to assuming this position in May 2007, Dr. Ehrich served as Vice President, Science Development and Chief Medical Officer of Alkermes. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., Inc. ("Merck"), a publicly traded pharmaceutical company, overseeing the clinical development and registration of novel pharmaceuticals. Dr. Ehrich is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. Dr. Ehrich worked as a research associate at the European Molecular Biology Laboratory in Heidelberg, Germany before attending medical school. Dr. Ehrich is a member of the scientific advisory board for Aileron Therapeutics, a privately held biopharmaceutical company.

Michael Landine

Mr. Michael J. Landine is Senior Vice President - Corporate Development of Alkermes Plc. Until September 16, 2011, Mr. Landine was Senior Vice President, Corporate Development of Alkermes. From March 1999 until May 2007, Mr. Landine served as Vice President, Corporate Development of Alkermes. From March 1988 until June 1998, he was Chief Financial Officer and Treasurer of Alkermes. Mr. Landine is a member of the board of directors of Kopin Corporation, a publicly traded manufacturer of components for electronic products, and ECI Biotech, a privately held protein sensor company. He served as a director of GTC Biotherapeutics, Inc., a publicly traded biotechnology company, from 2005 to 2010. Mr. Landine is a Certified Public Accountant.

Srdjan Stankovic

Dr. Srdjan Stankovic, M.D., MSPH has been appointed as Senior Vice President - Clinical Development of Alkermes plc., with effect from September 30, 2013. He brings more than 20 years of research and development (R&D) experience to Alkermes. He has led multidisciplinary development teams for small molecules and biologics in the therapeutic areas of psychiatry, neurology, oncology, pain and inflammation, respiratory medicine, cardiovascular medicine and stem cell therapy. Most recently, Dr. Stankovic held the position of Senior Vice President and Head of Global Clinical Development for Teva Pharmaceuticals. He was appointed to this role following Teva's acquisition of Cephalon, Inc., where he served as Senior Vice President, Worldwide Clinical Research, and was a member of the Executive Committee. In addition, Dr. Stankovic has held various executive management positions in the R&D organizations of UCB Pharma, Johnson & Johnson, Neurogen Corporation and Forest Laboratories, Inc., and is credited with several major new drug approvals, including KEPPRA(R) and NUVIGIL(R) . Dr. Stankovic completed his training in psychiatry at the University of Belgrade, Yugoslavia and his epidemiology training at the University of Alabama in Birmingham.

Mark Stejbach

Mr. Mark Stejbach is Senior Vice President, Chief Commercial Officer of Alkermes PLC. Prior to assuming this position, Mr. Stejbach served at Tengion, Inc. from 2008 to 2012, as its Chief Commercial Officer. He previously held senior positions at Merck & Co. and Biogen Idec Inc. and has 25 years of experience in biotech and pharmaceutical marketing, sales, managed care, and finance. Mr. Stejbach served on the charitable board of the Commonwealth National Fund from 2003 through 2011 and has served on the Advisory Board of the Center for Value-Based Insurance Design since 2009.

Peter Norman

Mr. Peter Norman has been appointed as Vice President - Government Affairs and Policy of Alkermes plc., with effect from September 30, 2013. He is a seasoned government affairs leader with significant experience in legislative and regulatory efforts as well as interactions with patient groups and healthcare coalitions on behalf of biopharmaceutical companies. He has worked on public policy strategies related to a range of pharmaceutical products, including drugs for Alzheimer's disease, obesity and diabetes, in addition to major healthcare issues, such as Medicare and Medicaid reimbursement, healthcare reform, DEA-controlled substance scheduling and biosimilars legislation. Most recently, Mr. Norman was head of the Washington, D.C. office of Eisai, Inc., where he directed government affairs and policy. Previously, he held government affairs positions for Amylin Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Novo Nordisk; and the Biotechnology Industry Organization (BIO). Mr. Norman earned a Juris Doctor from the University of Toledo College of Law in Ohio.

Paul Mitchell

Mr. Paul J. Mitchell is an Lead Independent Director of Alkermes Plc. From April 2003 to September 16, 2011, Mr. Mitchell served on Alkermes' board of directors. He served as the Chief Financial Officer and Treasurer of Kenet, Inc. from April 2002 until January 2009. Prior to joining Kenet, Mr. Mitchell was the Chief Financial Officer and Treasurer of Kopin Corporation from April 1985 through September 1998. From September 1998 through June 2001, Mr. Mitchell served in a consulting role at Kopin as Director of Strategic Planning. Prior to joining Kopin, Mr. Mitchell worked for the international accounting firm of Touche Ross & Co. from 1975 to 1984. Mr. Mitchell is President of Mitchell Financial Group and a member of the board of directors of several private companies. Mr. Mitchell is a Certified Public Accountant.

Nancy Wysenski

Ms. Nancy J. Wysenski is Director of Alkermes Plc., with effect from May 15, 2013. Most recently serving as Chief Commercial Officer at Vertex Pharmaceuticals Incorporated, Ms. Wysenski has more than 35 years of healthcare experience, nearly 30 years of which have been in leadership and commercial roles in the biopharmaceutical industry. During her tenure at Vertex, Ms. Wysenski was responsible for expanding and directing the company's sales, marketing, market research and sales operations activities for the company's first two commercial products, INCIVEK(R) and KALYDECO(R) . Under her leadership, these two products generated more than $1.5 billion in combined sales within the first 12 months, and INCIVEK achieved net sales of $1 billion in less than a year, faster than any previous pharmaceutical product. Prior to joining Vertex in 2009, Ms. Wysenski was Chief Operating Officer of Endo Pharmaceuticals, responsible for sales, marketing, commercial operations, outsourced production, supply chain management, human resources and business development activities, as well as the integration of Indevus Pharmaceuticals, Inc. following Endo's acquisition of the company. Ms. Wysenski was President and Chief Executive Officer of EMD Pharmaceuticals, Inc., the North American subsidiary of Merck KGaA, prior to joining Endo, and also served as EMD's Vice President of Commercial until 2001. Between 1984 and 1998, Ms. Wysenski held several sales-focused roles with Merck Human Health and Astra Merck, including Vice President of Field Sales for Astra Merck. Ms. Wysenski began her career in healthcare as a nurse in the Acute Psychiatry / Medical Teaching / Research Units at the Veteran's Administration Medical Center in Cleveland. Ms. Wysenski serves on the Board of Directors of Reata Pharmaceuticals, Inc. and North Carolina Central University's Board of Trustees.

David Anstice

Mr. David W. Anstice is an Independent Director of Alkermes Plc. From October 2008 to September 16, 2011, he served on Alkermes' board of directors. From 2006 to 2008, he served as Executive Vice President of Merck, with responsibility for enterprise strategy and implementation. During two separate parts of this period he was acting President, Global Human Health and President of Merck's business in Japan. From 2003 to 2006, Mr. Anstice served as President of Merck, with responsibility for Merck's Asia Pacific businesses. In his 34 years with Merck, held a positions with their worldwide ventures, including President, U.S. Human Health; President Human Health, the Americas; President, U.S./Canada; and President, Human Health, Europe. Mr. Anstice is Chairman and President of the board for the University of Sydney USA Foundation, a member of the board of the U.S. Studies Centre based at the University of Sydney, Australia and the Board of USA Foundation of the University of the Valley of Guatemala, a member of the U.S. Advisory Council for the American Australian Association in New York, a director of CSL Limited, a global specialty biopharmaceutical company, and an Adjunct Professor at the University of Sydney Business School.

Floyd Bloom

Dr. Floyd E. Bloom is an Independent Director of Alkermes Plc. Dr. Bloom is a founder of Alkermes, Inc. and from 1987 to September 16, 2011 served on Alkermes' board of directors. Dr. Bloom has been active in neuropharmacology for 35 years, holding positions at Yale University, the National Institute of Mental Health and The Salk Institute. From 1983 to February 2005, Dr. Bloom was the Chairman of the Neuropharmacology Department at The Scripps Research Institute and Professor Emeritus. Dr. Bloom served as Editor-in-Chief of Science from 1995 to May 2000. He is a member of the National Academy of Science, the Institute of Medicine, the Royal Swedish Academy of Science, Veteran's Administration—Gulf War Veterans Illness Research and the Washington University Board of Trustees. Dr. Bloom is a director of LZ Therapeutics, a privately held biopharmaceutical company. Dr. Bloom serves on the Scientific Advisory Boards of aTyr Pharma, Riverest and AgeneBio, Inc., all privately held pharmaceutical companies. Dr. Bloom served as a member of the board of directors of Elan from 2007 to 2009 and serves as an advisor to its Science and Technology Committee.

Robert Breyer

Mr. Robert A. Breyer is an Independent Director of Alkermes Plc. From July 1994 to September 16, 2011, Mr. Breyer served on Alkermes' board of directors. He served as the President of Alkermes from July 1994 until his retirement in December 2001 and Chief Operating Officer from July 1994 to February 2001. Prior to that time, Mr. Breyer was an executive and held various positions in the global pharmaceutical and medical device industries, including in the United States, the Netherlands, Belgium and Italy. Mr. Breyer served on the board of directors of Lentigen, Inc., a privately held, diversified biology company from 2007 to 2009. Mr. Breyer's experience as an executive in the pharmaceutical and medical device industries provides management and operational skills to the board of directors.

Wendy Dixon

Dr. Wendy L. Dixon is an Independent Director of Alkermes Plc. From January 2011 to September 16, 2011, Dr. Dixon served on Alkermes' board of directors. She has experience in the pharmaceutical and biotechnology industries, combining a technical background with experience in drug development, regulatory affairs and marketing. She directed the launches and growth of more than 20 pharmaceutical products. From 2001 to 2009 she was Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb where she served on the Executive Committee. From 1996 to 2001 she was Senior Vice President, Marketing at Merck and prior to that she held executive management positions at West Pharmaceuticals, Osteotech, and Centocor and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon is on the board of directors of Furiex Pharmaceuticals, Orexigen Therapeutics, Ardea Biosciences and Incyte Corporation, all publicly traded biotechnology or pharmaceutical companies, and was formerly on the board of Dentsply International. She is a Senior Advisor to The Monitor Group, a worldwide consulting firm.

Geraldine Henwood

Ms. Geraldine A. Henwood is an Independent Director of Alkermes Plc. From April 2003 to September 16, 2011, Ms. Henwood served on Alkermes' board of directors. She is the Chief Executive Officer/President and director of both Recro Pharma, a privately held specialty pharmaceutical company, and interim chief executive officer and board member of Garnet BioTherapeutics, Inc., a privately held clinical stage cell therapy company, and is a consultant with Malvern Consulting Group and SCP Partners. She is the co-founder of Auxilium Pharmaceuticals, Inc. and served as its President, Chief Executive Officer and director from 1999 to 2006. Prior to founding Auxilium, Ms. Henwood founded, in 1985, a contract research organization (CRO), IBAH, Inc. Prior to founding IBAH, Ms. Henwood was employed by SmithKline Beecham in various capacities including senior medical and regulatory positions. Ms. Henwood is a member of the board of directors of MAP Pharmaceuticals, Inc., a publicly traded pharmaceutical company and LZ Therapeutics, a privately held biopharmaceutical company, and previously served as a director of ImmunoScience, Inc., a privately held vaccine development company. She is a trustee of LaSalle Academy and Neumann University.

Options Compensation

Search Stocks